Santen Pharmaceutical Co., Ltd.
SNPHY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -25.38 | -0.74 | 8.33 | 1.73 |
| FCF Yield | 0.01% | 0.01% | 3.70% | 1.94% |
| EV / EBITDA | 4,690.61 | 40.18 | 23.11 | 29.75 |
| Quality | ||||
| ROIC | 0.02% | 1.85% | 2.12% | 2.78% |
| Gross Margin | 54.69% | 54.00% | 59.69% | 55.30% |
| Cash Conversion Ratio | 0.73 | 0.01 | 2.15 | 1.58 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.03% | 0.93% | 2.44% | 3.76% |
| Free Cash Flow Growth | -27.05% | -99.77% | 68.29% | -24.11% |
| Safety | ||||
| Net Debt / EBITDA | -610.71 | -7.01 | -3.18 | -4.92 |
| Interest Coverage | 24.91 | 62.07 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.53 | 0.60 | 0.68 |
| Cash Conversion Cycle | 24,179.74 | 136.31 | 120.05 | 118.85 |